Edgewise Therapeutics
Matt M. is currently working at Edgewise Therapeutics as the Sr. Director of Finance and Controller. Prior to this role, Matt worked at Ernst & Young LLP as an Audit Manager where Matt focused on industries such as biotech, pharmaceutical, technology, manufacturing, and real estate. Before that, Matt held a position as a Senior Valuation Analyst at Greener Equity, a boutique valuation and financial advisory firm. Matt also completed an internship at Ernst & Young LLP, specializing in industries such as private equity and hedge funds. Matt holds a Master of Accountancy degree in Accounting from Brigham Young University.
This person is not in any offices
Edgewise Therapeutics
1 followers
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it’s Series B financing round which will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. The company’s leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.